Takeda taps Innate for a new celiac approach

Takeda's interest in celiac disease has been apparent for some years, though its work so far has focused on targeting gluten with small molecules. Last week’s deal with Innate Pharma takes it into new territory – antibody drug conjugates. But others are already testing biological projects.